Hemostemix Closes Private Placement of $461,230

Executive Summary

• Hemostemix Inc. closed the first tranche of its non‑brokered private placement, raising $461,230 in gross proceeds.
• The offering consisted of 4,193,000 units at $0.11 per unit, each unit containing one common share and one warrant to purchase an additional share at $0.15 for two years (subject to accelerated expiry provisions).
• Net proceeds will be used for general working capital and to support marketing and sales of the company’s VesCell™ autologous stem‑cell therapy.

Key Details

• Units Issued: 4,193,000 units @ $0.11 per unit → $461,230 gross proceeds.
• Unit Composition: 1 common share + 1 common share purchase warrant (exercise price $0.15, 2‑year term).
• Accelerated Expiry Provision: If the TSX V average closing price exceeds $0.185 for any 10‑day period after four months and one day post‑closing, the company may accelerate warrant expiry to 30 days after a press release.
• Finder Compensation: Paid cash finder fees of $23,698.40 and issued 215,440 finder’s options (exercise price $0.15, 24‑month term).
• Use of Proceeds: General working capital; support ongoing operations, including marketing and sales of VesCell™ therapy.
• Related Party Transaction: Certain directors participated; the transaction qualifies for MI 61‑101 exemptions because neither fair market value nor consideration exceeds 25 % of market capitalization.
• Regulatory Conditions: Subject to exchange acceptance; securities subject to a four‑month hold period under Canadian securities law and any applicable foreign restrictions.

Notable Quotes

(No direct quotes were provided in the release.)